Skip to content

Author

J. Papenburg

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Respiratory Syncytial Virus–Related Hospitalizations Among Infants Receiving Nirsevimab

Key Points Question Was nirsevimab clinically effective against respiratory syncytial virus (RSV)–related emergency department (ED) visits, inpatient hospitalizations, and intensive care unit (ICU) admissions in Ontario and Quebec, Canada, during the 2024-2025 RSV season? Findings In this test-negative case-control stu...

S. A. Buchan, Jian-Ling Xie, M. Bhatt et al. · 0 citations
Sep 2026

Impact of the first nirsevimab immunization campaign on infant RSV-related emergency department visits and hospitalizations in Québec, Canada.

OBJECTIVES During the 2024-2025 respiratory syncytial virus (RSV) season, a universal nirsevimab infant immunization program was implemented in the province of Québec. We evaluated its population-level impact on RSV-related emergency department (ED) visits and hospitalizations in 0-5-month-old infants, using both activ...

Amandine Bemmo, Élise Fortin, P. Fortin et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.